Doença do neurônio motor: avaliação metabólica

Godoy, J. M.; Skacel, M.; Balassiano, S. L.; Neves, J. R. M.

doi:10.1590/S0004-282X1992000100013

Resumos

Com base nos escassos dados da literatura médica internacional, os autores estudam os níveis séricos e urinários de cálcio e fósforo, bem como a existência de possíveis anormalidades na coluna vertebral de 30 enfermos com o diagnóstico de doença do neurônio motor. Os autores postulam a participação de múltiplos fatores na etitfpatogenia da doença, fazendo menção aos aspectos tóxicos e metabólicos.

doença do neurônio motor; cálcio; fósforo

The authors studied serum and urinary calcium and phosphorus levels, as well as abnormalities on the spine of 30 piatients with motor neuron disease. The authors believe in multifactorial aspects in the pathogenesis of motor neuron disease, calling special attention to toxic and metabolic factors.

motor neuron disease; calcium; phosphorus

Doença do neurônio motor: avaliação metabólica

Motor neuron disease: a metabolic approach

J. M. Godoy^I; M. Skacel^II; S. L. Balassiano^III; J. R. M. Neves^III

^IProfessor Adjunto de Neurologia, UERJ

^IIProfessor Auxiliar de Neurologia, UERJ

^IIIProfessor Assistente de Neurologia, UERJ

RESUMO

Com base nos escassos dados da literatura médica internacional, os autores estudam os níveis séricos e urinários de cálcio e fósforo, bem como a existência de possíveis anormalidades na coluna vertebral de 30 enfermos com o diagnóstico de doença do neurônio motor. Os autores postulam a participação de múltiplos fatores na etitfpatogenia da doença, fazendo menção aos aspectos tóxicos e metabólicos.

Palavras chave: doença do neurônio motor, cálcio, fósforo.

SUMMARY

The authors studied serum and urinary calcium and phosphorus levels, as well as abnormalities on the spine of 30 piatients with motor neuron disease. The authors believe in multifactorial aspects in the pathogenesis of motor neuron disease, calling special attention to toxic and metabolic factors.

Key words: motor neuron disease, calcium, phosphorus.

Texto completo disponível apenas em PDF.

Full text available only in PDF format.

Trabalho realizado no Serviço de Neurologia do Hospital Universitário Pedro Ernesto (HUPE) da Universidade do Estado do Rio de Janeiro (UERJ).

Br. José Maurício Godoy - Rua Ozório Duque Estrada 74/902 B - 22451 Rio de Janeiro RJ -Brasil.

1. Baker LRI, Ackrill P, Cattel WR, Stamp TCB, Watson L. Iatrogenic osteomalacia and myopathy due to phosphate depletion. Br Med J 1974, 3:150-152.
2. Boothby JA, de Jesus PV, Rowland LP. Reversible forms of motor neuron disease (lead neuropathy). Arch Neurol 1974, 31:18-23.
3. Browder AA, Joselow MA, Louria DB. The problem of lead poisoning. Medicine 1973, 52:121-139.
4. Campbell AMG, Williams ER, Barltrop D. Motor neuron disease and exposure to lead. J Neurol Neurosurg Psychiatry 1970, 33:877-885.
5. Conradi S, Ronnevi L-O, Norris FH. Motor neuron disease and toxic metals. In Rowland LP (ed.): Human Motor Neuron Diseases. New York: Raven Press, 1982, p 201-231.
6. Conradi S, Ronnevi L-O, Vesterberg O. Abnormal tissue distribution of lead in amyotrophic lateral sclerosis. J. Neurol Sci 1976, 29:259-265.
7. De Lisle MB, Carpenter S. Neurofibrillary axonal swellings and amyotrophic lateral sclerosis. J Neurol Sci 1984, 63:241-250.
8. Goldstein GW, Wolinsky JS, Csejtev J. Isolated brain capillaries: A model for the study of lead encephalopathy. Ann Neurol, 1977, 1:235-249.
9. Houser CR, Crawford GD, Barber RP, Salvaterra PM, Vaughn JE. Organization and morphological characteristics of cholinergic neurons: an immunocytochemical study with a monoclonal antibody to choline acetyltransferase. Brain Res., 1983, 97:266-269.
10. Klaassen CD. Metais pesados e seus antagonistas. In Gilman AG, Goodman LS, Rail TW, Murad F (eds): As Bases Farmacológicas da Terapêutica. Rio de Janeiro: Guanabara Koogan, 1987, p 1053-1068.
11. Kurlander HM, Patten BM. Metals in spinal cord tissue of patients duing of motor neuron disease. Ann Neurol 1979, 6:21-24.
12. Livesley B, Sissons CE. Chronic lead intoxication mimicking motor neuron disease. Br Med J 1968, 4:387-388.
13. Mahaffey KR, Rader JI. Metabolic interactions: lead, calcium and iron. Ann NY Acad Sci 1980 : 355:285-297.
14. Mallette LE, Patten BM, Engel WK. Neuromuscular disease in secondary hyperparathyroidism. Ann Intern Med 1975, 82:474-483.
15. Miyiata S, Nakamura S, Nagata H, Kameyama M. Increased manganese level in spinal cords of amyotrophic lateral sclerosis determined by radiochemical neutron activation analysis. J Neurol Sci 1983, 61:283-293.
16. Nakagawa S, Yoshida S, Suematsu C, Shimizu El, Hirohata T, Kumamoto T, Yase Y, Kawai K, Iwata S. The calcium-magnesium deficient rat: a study on the distribution of calcium in the spinal cord using the electron probe microanalyser. Experientia 1977, 33:1225-1226.
17. Nakano Y. Changes in cell bodies and proximal axons of large motor neurons (LMN) and argentophilic neurofilament (NF) accumulation in the anterior horn of ALS patients (Abstr). J Neuropath Exp Neurol 1987, 46:341.
18. Patten BM, Bilezikian JP, Mallette LE, Prince A, Engel WK, Aurbach GD. Neuro-muscular disease in primary hyperparathyroidism. Ann Intern Med 1974, 80:182-193.
19. Patten BM, Engel WK. Phosphate and parathyroid disorders associated with the syndrome of amyotrophic lateral sclerosis. In Rowland DP (ed), Human Motor Neuron Diseases. New York: Raven Press, 1982, p 181-200.
20. Prineas JW, Mason AS, Henson RA. Myopathy in metabolic bone disease. Br Med J 1965, 1:1034-1036.
21. Schanne FAX, Kane AB, Young EE, Farber JD. Calcium dependence of toxic cell death: a final common pathway. Science 1979, 206:700-702.
22. ScElaepfer WW. Neurofilaments: structure, metabolism and implications in disease. J Neuropath Exp Neurol 1987, 46:117-129.
23. Schott GD, Wills MR. Myopathy in hypophosphataemic osteomalacia presenting in adult life. J Neurol Neurosurg Psychiatry 1975, 38:297-304.
24. Silbergeld EK, Adler HS. Subcellular mechanisms of lead neurotoxicity. Brain Res 1978, 148:451-457.
25. Silbergeld EK, Fales IT, Goldberg AM. The effects of inorganic lead on the neuro-muscular junction. Neuropharmacology 1974, 13:795-801.
26. Simpson JA, Seaton DA, Adams JF. Response to treatment with chelating agents of anaemia, chronic encephalopathy land myelopathy due to lead poisoning. J Neurol Neurosurg Psychiatry 1974, 37:536-541.
27. Smith R, Stern G. Myopathy, osteomalacia and hyperparathyroidism. Brain 1967, 90:593-602.
28. Spencer PS. ALS: toxic hypothesis old and new. Muscle & Nerve 1986, 9 (suppl) :56.
29. Thesleff S. Different kinds of acetylcholine release from the motor nerve. In Smythies JR, RJ Bradley RJ (eds): International Review of Neurobiology, vol 28. London: Academic Press, 1986, p 59-62.
30. Vioale CT. Diagnostic features of muscular syndrome resulting from hyperparathyroidism, osteomalacia owing to renal tubular acidosis and perhaps to related disorders of calcium metabolism. Trans Am Neurol Assoc 1949, 74:143-147.
31. Yanagihara R. Heavy metals and essential minerals in motor neuron diseases. In Rowland LP (ed): Human Motor Neuron Diseases. New York: Raven Press, 1982, p 233-247.
32. Yanagihara R, Garruto RM, Gajdusek DC. Calcium and vitamin D metabolism in Guamanian Chamorros with ALS and parkinsonism-dementia. Ann Neurol 1984, 15:12-18.
33. Yase Y. The pathogenesis of amyotrophic lateral sclerosis. Lancet 1972, 2:292-296.
34. Yase Y, Yano I, Uebayashi Y, Yoshida S, Yoshimasu F. Pathogenetic role of aluminium in amyotrophic lateral sclerosis. Muscle & Nerve 1986, 9 (suppl) :109.
35. Whitehouse PJ, Wamsley JK, Zarbin MA, Price DL, Tourtellotte WW, Kuhar MJ. Amyotrophic lateral sclerosis: alterations in neurotransmitter receptors. Ann Neurol 1983, 14:8-16.

Datas de Publicação

Publicação nesta coleção
22 Fev 2011
Data do Fascículo
Mar 1992

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

[1] 1. Baker LRI, Ackrill P, Cattel WR, Stamp TCB, Watson L. Iatrogenic osteomalacia and myopathy due to phosphate depletion. Br Med J 1974, 3:150-152.

[2] 2. Boothby JA, de Jesus PV, Rowland LP. Reversible forms of motor neuron disease (lead neuropathy). Arch Neurol 1974, 31:18-23.

[3] 3. Browder AA, Joselow MA, Louria DB. The problem of lead poisoning. Medicine 1973, 52:121-139.

[4] 4. Campbell AMG, Williams ER, Barltrop D. Motor neuron disease and exposure to lead. J Neurol Neurosurg Psychiatry 1970, 33:877-885.

[5] 5. Conradi S, Ronnevi L-O, Norris FH. Motor neuron disease and toxic metals. In Rowland LP (ed.): Human Motor Neuron Diseases. New York: Raven Press, 1982, p 201-231.

[6] 6. Conradi S, Ronnevi L-O, Vesterberg O. Abnormal tissue distribution of lead in amyotrophic lateral sclerosis. J. Neurol Sci 1976, 29:259-265.

[7] 7. De Lisle MB, Carpenter S. Neurofibrillary axonal swellings and amyotrophic lateral sclerosis. J Neurol Sci 1984, 63:241-250.

[8] 8. Goldstein GW, Wolinsky JS, Csejtev J. Isolated brain capillaries: A model for the study of lead encephalopathy. Ann Neurol, 1977, 1:235-249.

[9] 9. Houser CR, Crawford GD, Barber RP, Salvaterra PM, Vaughn JE. Organization and morphological characteristics of cholinergic neurons: an immunocytochemical study with a monoclonal antibody to choline acetyltransferase. Brain Res., 1983, 97:266-269.

[10] 10. Klaassen CD. Metais pesados e seus antagonistas. In Gilman AG, Goodman LS, Rail TW, Murad F (eds): As Bases Farmacológicas da Terapêutica. Rio de Janeiro: Guanabara Koogan, 1987, p 1053-1068.

[11] 11. Kurlander HM, Patten BM. Metals in spinal cord tissue of patients duing of motor neuron disease. Ann Neurol 1979, 6:21-24.

[12] 12. Livesley B, Sissons CE. Chronic lead intoxication mimicking motor neuron disease. Br Med J 1968, 4:387-388.

[13] 13. Mahaffey KR, Rader JI. Metabolic interactions: lead, calcium and iron. Ann NY Acad Sci 1980 : 355:285-297.

[14] 14. Mallette LE, Patten BM, Engel WK. Neuromuscular disease in secondary hyperparathyroidism. Ann Intern Med 1975, 82:474-483.

[15] 15. Miyiata S, Nakamura S, Nagata H, Kameyama M. Increased manganese level in spinal cords of amyotrophic lateral sclerosis determined by radiochemical neutron activation analysis. J Neurol Sci 1983, 61:283-293.

[16] 16. Nakagawa S, Yoshida S, Suematsu C, Shimizu El, Hirohata T, Kumamoto T, Yase Y, Kawai K, Iwata S. The calcium-magnesium deficient rat: a study on the distribution of calcium in the spinal cord using the electron probe microanalyser. Experientia 1977, 33:1225-1226.

[17] 17. Nakano Y. Changes in cell bodies and proximal axons of large motor neurons (LMN) and argentophilic neurofilament (NF) accumulation in the anterior horn of ALS patients (Abstr). J Neuropath Exp Neurol 1987, 46:341.

[18] 18. Patten BM, Bilezikian JP, Mallette LE, Prince A, Engel WK, Aurbach GD. Neuro-muscular disease in primary hyperparathyroidism. Ann Intern Med 1974, 80:182-193.

[19] 19. Patten BM, Engel WK. Phosphate and parathyroid disorders associated with the syndrome of amyotrophic lateral sclerosis. In Rowland DP (ed), Human Motor Neuron Diseases. New York: Raven Press, 1982, p 181-200.

[20] 20. Prineas JW, Mason AS, Henson RA. Myopathy in metabolic bone disease. Br Med J 1965, 1:1034-1036.

[21] 21. Schanne FAX, Kane AB, Young EE, Farber JD. Calcium dependence of toxic cell death: a final common pathway. Science 1979, 206:700-702.

[22] 22. ScElaepfer WW. Neurofilaments: structure, metabolism and implications in disease. J Neuropath Exp Neurol 1987, 46:117-129.

[23] 23. Schott GD, Wills MR. Myopathy in hypophosphataemic osteomalacia presenting in adult life. J Neurol Neurosurg Psychiatry 1975, 38:297-304.

[24] 24. Silbergeld EK, Adler HS. Subcellular mechanisms of lead neurotoxicity. Brain Res 1978, 148:451-457.

[25] 25. Silbergeld EK, Fales IT, Goldberg AM. The effects of inorganic lead on the neuro-muscular junction. Neuropharmacology 1974, 13:795-801.

[26] 26. Simpson JA, Seaton DA, Adams JF. Response to treatment with chelating agents of anaemia, chronic encephalopathy land myelopathy due to lead poisoning. J Neurol Neurosurg Psychiatry 1974, 37:536-541.

[27] 27. Smith R, Stern G. Myopathy, osteomalacia and hyperparathyroidism. Brain 1967, 90:593-602.

[28] 28. Spencer PS. ALS: toxic hypothesis old and new. Muscle & Nerve 1986, 9 (suppl) :56.

[29] 29. Thesleff S. Different kinds of acetylcholine release from the motor nerve. In Smythies JR, RJ Bradley RJ (eds): International Review of Neurobiology, vol 28. London: Academic Press, 1986, p 59-62.

[30] 30. Vioale CT. Diagnostic features of muscular syndrome resulting from hyperparathyroidism, osteomalacia owing to renal tubular acidosis and perhaps to related disorders of calcium metabolism. Trans Am Neurol Assoc 1949, 74:143-147.

[31] 31. Yanagihara R. Heavy metals and essential minerals in motor neuron diseases. In Rowland LP (ed): Human Motor Neuron Diseases. New York: Raven Press, 1982, p 233-247.

[32] 32. Yanagihara R, Garruto RM, Gajdusek DC. Calcium and vitamin D metabolism in Guamanian Chamorros with ALS and parkinsonism-dementia. Ann Neurol 1984, 15:12-18.

[33] 33. Yase Y. The pathogenesis of amyotrophic lateral sclerosis. Lancet 1972, 2:292-296.

[34] 34. Yase Y, Yano I, Uebayashi Y, Yoshida S, Yoshimasu F. Pathogenetic role of aluminium in amyotrophic lateral sclerosis. Muscle & Nerve 1986, 9 (suppl) :109.

[35] 35. Whitehouse PJ, Wamsley JK, Zarbin MA, Price DL, Tourtellotte WW, Kuhar MJ. Amyotrophic lateral sclerosis: alterations in neurotransmitter receptors. Ann Neurol 1983, 14:8-16.